Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also dev… Read more
Opus Genetics, Inc. (IRD) - Total Assets
Latest total assets as of September 2025: $36.12 Million USD
Based on the latest financial reports, Opus Genetics, Inc. (IRD) holds total assets worth $36.12 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Opus Genetics, Inc. - Total Assets Trend (2019–2024)
This chart illustrates how Opus Genetics, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Opus Genetics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Opus Genetics, Inc.'s total assets of $36.12 Million consist of 99.3% current assets and 0.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.3% |
| Accounts Receivable | $5.77 Million | 15.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Opus Genetics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Opus Genetics, Inc.'s current assets represent 99.3% of total assets in 2024, an increase from 98.8% in 2019.
- Cash Position: Cash and equivalents constituted 82.3% of total assets in 2024, down from 86.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 15.7% of total assets.
Opus Genetics, Inc. Competitors by Total Assets
Key competitors of Opus Genetics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Opus Genetics, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Opus Genetics, Inc. generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Opus Genetics, Inc. is currently not profitable relative to its asset base.
Opus Genetics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.23 | 6.63 | 5.55 |
| Quick Ratio | 1.23 | 6.63 | 5.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.82 Million | $ 34.30 Million | $ 14.48 Million |
Opus Genetics, Inc. - Advanced Valuation Insights
This section examines the relationship between Opus Genetics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 56.05 |
| Latest Market Cap to Assets Ratio | 4.25 |
| Asset Growth Rate (YoY) | -31.7% |
| Total Assets | $36.86 Million |
| Market Capitalization | $156.71 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Opus Genetics, Inc.'s assets at a significant premium ( 4.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Opus Genetics, Inc.'s assets decreased by 31.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Opus Genetics, Inc. (2019–2024)
The table below shows the annual total assets of Opus Genetics, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $36.86 Million | -31.67% |
| 2023-12-31 | $53.95 Million | +10.12% |
| 2022-12-31 | $48.99 Million | +87.87% |
| 2021-12-31 | $26.08 Million | +47.48% |
| 2020-12-31 | $17.68 Million | +891.14% |
| 2019-12-31 | $1.78 Million | -- |